- Home
- MLCI vs ALGS Comparison
MLCI vs ALGS Comparison
Compare MLCI & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MLCI | ALGS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.6M | 34.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MLCI | ALGS |
|---|---|---|
| Price | $3.41 | $6.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 30.1K | ★ 115.6K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.68 | $4.80 |
| 52 Week High | $8.68 | $13.69 |
Technical Indicators
Market Signals| Indicator | MLCI | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 52.56 | 55.80 |
| Support Level | $3.31 | $4.80 |
| Resistance Level | $3.84 | $6.82 |
| Average True Range (ATR) | 0.28 | 0.51 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 58.76 | 50.56 |
Price Performance
Historical ComparisonAbout MLCI Mount Logan Capital Inc.
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The company's reporting segments include asset management and insurance. The company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The Asset Management segment comprises all fee generating activities. The Insurance Solutions segment, which derives maximum revenue, consists of two product lines within the insurance business, LTC and MYGA.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.